Ohio Valley Node-Network (OVNN) of the NIDA Clinical Trials Network: (MOMs2)

The primary objective of this trial is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release (XR) buprenorphine (BUP) compared to sublingual (SL) BUP on mother and infant outcomes. The primary hypotheses are that the BUP-XR, relative to the BUPSL, group will have significantly: 1) less illicit opioid use during pregnancy; 2) shorter infant hospital length of stay (LOS); and 3) greater postpartum BUP adherence. Testing conceptual models of the mechanisms by which BUP-XR may improve mother-infant outcomes, relative to BUP-SL, is a secondary trial objective.